Business
OncoSec Medical Announces FINRA Approval of Reverse Stock Split
OncoSec Medical Announces FINRA Approval of Reverse Stock Split.
About this update from Oncosec Medical Incorporated
[{"type":"text","content":"\n\n\n\nOncoSec Medical Announces FINRA Approval of Reverse Stock Split\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nOncoSec Medical Announces FINRA Approval of Reverse Stock Split\nPR Newswire\nSAN DIEGO, May 15, 2015\n\n\n\nSAN DIEGO, May 15, 2015 /PRNewswire/ -- OncoSec Medical Inc. (\"OncoSec\") (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Financial Industry Regulatory Authority (\"FINRA\") has approved the company's 1-for-20 reverse stock split. According to FINRA's approval, the reverse stock split will become effective and OncoSec's common stock will begin trading on a post-split basis before the open of trading on May 18, 2015.\n\n\nOncoSec's common stock will trade under the ticker symbol \"ONCSD\" for a period of 20 business days as a result of the reverse stock split, and common shares will also trade under a new CUSIP number 68234L207.\n\nAt the effective time of the 1-for-20 reverse stock split, every 20 shares of issued and outstanding common stock will be converted into 1 share of issued and outstanding common stock, and the authorized shares of common stock will be reduced from 3,200,000,000 to 160,000,000 shares. All fractional shares of common stock will be rounded up to the nearest whole share. Immediately after the reverse stock split becomes effective, the company will have approximately 12,350,132 shares of common stock outstanding.\n\nFor additional insight into the company's reverse stock split and future plans, please visit the \"CEO's Perspective\" on OncoSec's website: http://oncosec.com/ceo-perspective-reverse-split-and-uplisting. \n\nAbout OncoSec Medical Inc. OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse™ have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treat...